BEAM

Beam Therapeutics Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1745999Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$0.14B

Net Income FY2025

$(0.08B)

EPS (Basic, as reported)

$-0.81

Net Margin FY2025

-57.2%

ROE FY2025

-6.5%

Total Equity

$1.24B

Shares Out

103M

Business description

Beam Therapeutics Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 140

Fiscal yearFY2019⚑FY2020FY2021FY2022FY2023FY2024FY2025

Revenue00526137864140

Research & development(55)(103)(387)(312)(437)(368)(410)

General & administrative(21)(30)(57)(88)(117)(112)(114)

Total operating expenses(75)(133)(444)(399)(554)(479)(523)

Operating income(75)(133)(392)(338)(176)(416)(384)

Other income (expense), net(3)(62)22784539304

Pre-tax income—(195)(371)(260)(131)(377)(80)

Income tax expense000(3)(1)00

Net income(78)(195)(371)(289)(133)(377)(80)

EPS — basic($14.05)($4.19)($5.77)($4.13)($1.72)($4.58)($0.81)

EPS — diluted($14.05)($4.19)($5.77)($4.13)($1.72)($4.58)($0.81)

Shares outstanding — basic (M)6476470778299

Shares outstanding — diluted (M)6476470778299

⚑ Weighted-average shares changed ×7.83 between FY2019 and FY2020 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.